Animals treated with R848-BPDs combined with anti–PD-1 showed better tumor control (P < 0.0001) and longer-term survival compared to mice given free R848 in combination with anti–PD-1 or anti–PD-1 alone (Fig. 5, C and D). This evidence concerns the gene PDCD1 and neoplasm.